Medicines and Healthcare products Regulatory Agency

Terlipressin: new recommendations to reduce risks of respiratory failure and septic shock in patients with type 1 hepatorenal syndrome

Regulatory · Tier 1, UK official · UK · 2023-03

Current — checked with the publisher on 2026-09-01

https://www.gov.uk/drug-safety-update/terlipressin-new-recommendations-to-reduce-risks-of-respiratory-failure-and-septic-shock-in-patients-with-type-1-hepatorenal-syndrome

What this platform has drawn from it — 6 claims

How this record was checked, and what is doubtful about it

Drug Safety Update page fetched and read in full by two independent agents. It is the UK regulatory position on terlipressin and it is the safety envelope that the NICE CG141 terlipressin recommendation does not carry. Note: this document contains no dose, no infusion rate and no maximum duration for terlipressin - the second agent searched the whole page specifically to confirm that.

Verification: verified · last accessed 2026-09-01 · status checked against https://www.gov.uk/drug-safety-update